Chemically modified antiviral peptides against SARS-CoV-2

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, remains a significant global health threat.
• While vaccines and antivirals exist, novel therapeutic strategies are crucial.
• SARS-CoV-2 infection involves multiple stages, offering targets for intervention.

Purpose of the Study:

• To review modified antiviral peptides targeting SARS-CoV-2.
• To explore peptides acting on different viral replication stages.
• To highlight peptides for improved stability, efficacy, and specificity.

Main Methods:

• Literature review of modified peptides against SARS-CoV-2.
• Analysis of peptides targeting ACE2-RBD interaction.
• Examination of peptides inhibiting membrane fusion.
• Review of peptides acting on viral proteases.

Main Results:

• Modified peptides demonstrate potential for enhanced stability and specificity.
• Peptides targeting viral entry (ACE2-RBD, fusion) show promise.
• Peptides inhibiting viral proteases offer alternative therapeutic avenues.
• Structural modifications can improve peptide affinity and efficacy.

Conclusions:

• Modified antiviral peptides represent a viable therapeutic strategy against SARS-CoV-2.
• Targeting specific viral replication steps with peptides can disrupt infection.
• Further research into peptide design can lead to potent COVID-19 therapeutics.